Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Sep 25;167(1):277–288. doi: 10.1007/s10549-017-4507-y

Figure 2. Kaplan-Meier Curves: Hormone Receptor Positive (HR+)/Her2− (Event-free and Overall survival): Stratified by Tamoxifen vs. Aromatase Inhibitor (AI) use.

Figure 2

In HR+ women, there is a significant interaction between hormonal therapy and obesity with overall survival (OS), and in women receiving tamoxifen only, but not AIs, obesity is associated with significantly worse OS. There is no significant interaction with event-free survival, although effects are in the same direction.